GeneDx Holdings Corp
NASDAQ:WGS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
56.36
167.515
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
GeneDx Holdings Corp
Other Long-Term Assets
GeneDx Holdings Corp
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
GeneDx Holdings Corp
NASDAQ:WGS
|
Other Long-Term Assets
$4.3m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Other Long-Term Assets
$296m
|
CAGR 3-Years
31%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
CVS Health Corp
NYSE:CVS
|
Other Long-Term Assets
$7.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
17%
|
|
|
Cigna Corp
NYSE:CI
|
Other Long-Term Assets
$15.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
47%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Other Long-Term Assets
$648.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Other Long-Term Assets
$151m
|
CAGR 3-Years
43%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
GeneDx Holdings Corp
Glance View
GeneDx Holdings Corp. holds a prominent spot in the realm of genetic testing and diagnostics, intertwining advanced technology with healthcare to create a substantial impact in personalized medicine. Originally founded with the mission to provide accessible genetic testing services, the company has evolved into a pivotal player in identifying rare genetic disorders through its specialized sequencing techniques. By leveraging next-generation sequencing (NGS), GeneDx can efficiently decode vast arrays of genetic information, enabling healthcare providers to diagnose and manage hereditary conditions more accurately. Their comprehensive test offerings cover everything from whole exome sequencing to disease-specific panels, catering to the needs of patients and clinicians alike. This tailored approach not only drives innovation but also establishes a firm foundation in genetic diagnostics, addressing some of the most pressing needs in modern medicine. In terms of revenue generation, GeneDx’s business model thrives on its collaborations with healthcare institutions, insurers, and research organizations. The company's ability to reduce the time and cost involved in traditional diagnostics creates a clear value proposition, encouraging widespread adoption of its services. Insurance reimbursements play a crucial role, as more healthcare policies expand to include genetic testing due to its significant potential for early disease detection and management. Moreover, strategic partnerships and continuous investments in research and development allow GeneDx to stay at the forefront of genomic insights, further strengthening its market position. By staying ahead of industry trends and focusing on expanding access to genetic information, GeneDx establishes itself not only as a leader in diagnostics but also as an integral force in the broader healthcare ecosystem, ensuring sustained growth and relevance.
See Also
What is GeneDx Holdings Corp's Other Long-Term Assets?
Other Long-Term Assets
4.3m
USD
Based on the financial report for Dec 31, 2024, GeneDx Holdings Corp's Other Long-Term Assets amounts to 4.3m USD.
What is GeneDx Holdings Corp's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-2%
Over the last year, the Other Long-Term Assets growth was -2%. The average annual Other Long-Term Assets growth rates for GeneDx Holdings Corp have been -18% over the past three years , -2% over the past five years .